Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction.
about
The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fractionHeart failure with preserved ejection fraction: mechanisms, clinical features, and therapiesPlasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction StudyMyocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titinMetabolomic fingerprint of heart failure with preserved ejection fraction.Dasatinib Attenuates Pressure Overload Induced Cardiac Fibrosis in a Murine Transverse Aortic Constriction ModelSerum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction.Biomechanics of Cardiac FunctionPrediction of All-Cause Mortality Based on the Direct Measurement of Intrathoracic Impedance.Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Follistatin like 1 Regulates Hypertrophy in Heart Failure with Preserved Ejection FractionDiagnosing heart failure with preserved ejection fraction.Circulating biomarkers in patients with heart failure and preserved ejection fraction.Heart failure biomarkers at point-of-care: current utilization and future potential.Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use.Phenomapping for the Identification of Hypertensive Patients with the Myocardial Substrate for Heart Failure with Preserved Ejection Fraction.Novel plasma and imaging biomarkers in heart failure with preserved ejection fraction.Lung ultrasound as a translational approach for non-invasive assessment of heart failure with reduced or preserved ejection fraction in mice.Biomarkers and heart disease: what is translational success?Guidelines for translational research in heart failure.Understanding cardiac extracellular matrix remodeling to develop biomarkers of myocardial infarction outcomes.Syndecan-4 is a key determinant of collagen cross-linking and passive myocardial stiffness in the pressure-overloaded heart.Response by Methawasin and Granzier to Letter Regarding Article, "Experimentally Increasing the Compliance of Titin Through RNA Binding Motif-20 (RBM20) Inhibition Improves Diastolic Function in a Mouse Model of Heart Failure With Preserved EjectionPrognostication in Different Heart Failure Phenotypes: The Role of Circulating Biomarkers.Predictive Value of Collagen Biomarkers for Heart Failure With and Without Preserved Ejection Fraction: MESA (Multi-Ethnic Study of Atherosclerosis).Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview.
P2860
Q26765101-00C1DB7D-C94A-444C-9454-0291B55985FEQ27000263-ED8C5342-1B3D-467F-A9FB-450F6594F8D6Q31036336-49864344-1CE7-4103-BC69-58D11D226227Q35328760-CAC25547-13D5-497D-ABF5-2DA204C0B837Q35641415-82E841DE-EEA0-4DEB-90B1-CABD4414F0D2Q35803480-9686A318-3970-408F-9976-571F8883CE72Q36171125-2A4E8F86-FD60-4633-AEF8-1E162FD7D55DQ36343041-C46DB585-2EFF-4CB1-8CC1-843FD5FB4C4EQ36407204-1D65FD33-2434-4AD2-B4D6-DCCA617247E3Q37058596-98ACD1C3-D4F8-4A76-9790-294084C952BEQ37094365-060F5A29-3B38-41CF-879A-F1231AAABD33Q38127754-98471E12-CD3F-4519-A470-D14851688548Q38152289-B444475F-01FC-448E-A775-A0CC50702E0CQ38187750-9A051C92-9CE7-409D-9F1D-17B516E26B99Q38614176-BC8A878D-7B82-4D97-9416-995F3489CB00Q38930342-87A22C5F-7B18-4E34-8570-B788FB0D2797Q40963394-DCA901E9-DB5C-4DC5-9C11-1B50436B3864Q42030547-F28F261C-782C-4780-B984-478EF53D86C0Q42084887-AE81BC1C-3A6D-4EAB-98BF-95AC35E75FABQ47573464-2568529A-975F-48F5-92D5-734A3DF834C3Q47677252-F922200B-5C17-4047-8E12-7658A2265B8FQ52656588-844E2F9D-9F27-4554-9223-AABE1DD302BEQ55153763-661EFEC8-46FC-4D58-B140-8028FAD2A207Q55343200-34DC9711-A0E7-41B7-BB8F-0A3259B298F2Q55434646-2F9C113F-255B-4313-B512-CCD2A9898D0DQ55610979-D4C09272-EFA6-4F32-80F2-51D43F921500
P2860
Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Biomarkers of diastolic dysfun ...... a preserved ejection fraction.
@en
type
label
Biomarkers of diastolic dysfun ...... a preserved ejection fraction.
@en
prefLabel
Biomarkers of diastolic dysfun ...... a preserved ejection fraction.
@en
P2860
P921
P1476
Biomarkers of diastolic dysfun ...... a preserved ejection fraction
@en
P2093
Catalin F Baicu
P2860
P2888
P304
P356
10.1007/S12265-013-9472-1
P407
P577
2013-05-29T00:00:00Z
P6179
1024547702